November 4th, 2026November 2026 preview: 4 FDA decisions to watch in pediatric careFind out the 4 FDA decisions to watch in November 2026 for pediatric care.Read more
November 20th, 2026Contemporary Pediatrics week in review: November 16-20, 2026Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.Read more
November 20th, 2026FDA approves once-weekly somapacitan for children with Turner syndromeThe FDA approved once-weekly somapacitan-beco for growth failure in Turner syndrome in children aged 2.5+ years, based on phase 3 REAL8 data.Read more
November 20th, 2026Puberty brings new cardiovascular risks for girlsExperts explain how puberty affects lipid levels, body composition, and mental health, with implications for cardiovascular screening in adolescent girls.Read more
November 20th, 2026New AHA advisory calls for lifelong cardiovascular care in womenExperts discuss a new AHA advisory linking cardiovascular risk across a woman's life, from puberty through pregnancy, menopause, and beyond.Read more
November 19th, 2026Tofacitinib curbs interferon signaling in Down syndrome phase 2 trialIn a phase 2 trial, tofacitinib met its safety end point and lowered interferon and cytokine scores in adolescents and adults with Down syndrome.Read more
November 19th, 2026FDA approves venglustat for neurological symptoms of GD3The FDA approved oral venglustat for neurological symptoms of type 3 Gaucher disease in patients ≥15 kg, based on phase 3 LEAP2MONO data.Read more
November 18th, 2026Eczema linked to higher odds of sleep disturbance in childrenEczema was linked to 28% higher odds of sleep disturbance in a 26,395-patient pediatric primary care cohort presented at ACAAI 2026.Read more